Holen Sie sich die Stockscreener-App
1.49
3.85%
0.06
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated capital growth - Autocar Professional
What drives Zentalis Pharmaceuticals Inc. stock priceExplosive trading opportunities - Autocar Professional
What analysts say about Zentalis Pharmaceuticals Inc. stockFree Trading Strategy Suggestions - printweek.in
Is Zentalis Pharmaceuticals Inc. a good long term investmentExplosive returns - jammulinksnews.com
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - Newser
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyHigh Return Investment Tips - Newser
How Zentalis Pharmaceuticals Inc. stock performs during market volatilityDaily Swing Candidates - Newser
Insider Stock Buyers At Zentalis Pharmaceuticals Recouped Some Losses This Week - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Purchases 33,958 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Completeness Index - MarketScreener
Zentalis Pharmaceuticals shareholders elect three directors at annual meeting - Investing.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE - Defense World
Squarepoint Ops LLC Reduces Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Ameriprise Financial Inc. Purchases New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - The Globe and Mail
ProShare Advisors LLC Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Why Did Zentalis Pharmaceuticals Inc. (ZNTL) Plunge 11.33%? - AInvest
Nuveen Asset Management LLC Has $1.94 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Research Team: 137K Share Options Granted to Key New Hires - Stock Titan
Zentalis Pharmaceuticals Presents Promising Study Results at ASCO - TipRanks
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
BNP Paribas Financial Markets Invests $534,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Captrust Financial Advisors Buys New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts - Defense World
Jane Street Group LLC Boosts Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference - TipRanks
Balyasny Asset Management L.P. Has $175,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Wedbush Issues Optimistic Outlook for ZNTL Earnings - Defense World
Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - Yahoo Finance
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
ZNTL Advances Azenosertib Development Amid Strategic Progress | - GuruFocus
Analyst Reiterates Neutral Rating for Zentalis Pharma (ZNTL) | Z - GuruFocus
ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developme - GuruFocus
ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developments | ZNTL Stock News - GuruFocus
Zentalis Pharma (ZNTL) Receives Buy Rating from HC Wainwright & Co. | ZNTL Stock News - GuruFocus
4.55%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):